Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) † † The study was previously presented as an oral presentation at the 33rd Annual Meeting of the American Society of Clinical Oncology; 3–5 June 2011; Chicago, IL, USA.
Titel:
Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) † † The study was previously presented as an oral presentation at the 33rd Annual Meeting of the American Society of Clinical Oncology; 3–5 June 2011; Chicago, IL, USA.
Auteur:
Gerber, B. Loibl, S. Eidtmann, H. Rezai, M. Fasching, P.A. Tesch, H. Eggemann, H. Schrader, I. Kittel, K. Hanusch, C. Kreienberg, R. Solbach, C. Jackisch, C. Kunz, G. Blohmer, J.U. Huober, J. Hauschild, M. Nekljudova, V. Untch, M. von Minckwitz, G.